2027 ICD-10-CM Diagnosis Code D61.82Myelophthisis
ICD-10-CM Codes›D50–D89›D60-D64›D61
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 109
- Chronic Condition
D61.82 is a billable ICD-10-CM diagnosis code for myelophthisis. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 820 through 825, 840 through 842. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 41 closely related codes. Coders also document this condition as myelophthisic anemia. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Aplastic anemia.
For Medicare Advantage risk adjustment, D61.82 maps to CMS-HCC Category 109 (Acquired Hemolytic, Aplastic, and Sideroblastic Anemias) under the V28 model, adding a risk factor of about 1.144 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
D61.82 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Myelophthisic anemia
- Myelophthisis
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to D61.82: its own notes plus those printed at D61 and Chapter 3. A note printed at a category, block or chapter applies to every code under it.
Applicable To
Conditions this code is used for: synonyms of the title or, for "other specified" codes, the conditions assigned to it. The list is not exhaustive.
- Leukoerythroblastic anemia
- Myelophthisic anemia
- Panmyelophthisis
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Excludes2
Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.
- neutropenia (D70.-)
- autoimmune disease (systemic) NOS (M35.9)
- certain conditions originating in the perinatal period (P00-P96)
- complications of pregnancy, childbirth and the puerperium (O00-O9A)
- congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
- endocrine, nutritional and metabolic diseases (E00-E88)
- human immunodeficiency virus [HIV] disease (B20)
- injury, poisoning and certain other consequences of external causes (S00-T88)
- neoplasms (C00-D49)
- symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)
Code Also
A second code may be needed to fully describe the condition; the note gives no sequencing direction.
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name D61.82, its category, or a range that includes it.
Excludes1 7
These codes carry an Excludes1 note naming D61.82: they are not reported together with it, unless the two conditions are unrelated.
- D47.1 Chronic myeloproliferative diseasemyelophthisic anemia (D61.82)
- D47.1 Chronic myeloproliferative diseasemyelophthisis (D61.82)
- D61.81 Pancytopeniapancytopenia (due to) (with) bone marrow infiltration (D61.82)
- D61.81 Pancytopeniapancytopenia (due to) (with) leukoerythroblastic anemia (D61.82)
- D75.81 Myelofibrosisleukoerythroblastic anemia (D61.82)
- D75.81 Myelofibrosismyelophthisic anemia (D61.82)
- D75.81 Myelofibrosismyelophthisis (D61.82)
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) D64.9
leukoerythroblastic D61.82
myelophthisic D61.82
normocytic (infectional) D64.9
myelophthisic D61.82
Myelophthisis D61.82
Panmyelophthisis D61.82
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Myelophthisis
a condition resulting from the destruction of bone marrow precursor cells and their stroma. bone marrow is displaced by fibrosis, tumors, or granulomas.
Patient EducationClinical
Bone Marrow Diseases
Bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains stem cells. The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets that help with blood clotting.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert D61.82 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About D61.82Overview
What is the ICD-10 code for myelophthisis?
The ICD-10-CM code for myelophthisis is D61.82 (sometimes written as D6182). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is D61.82 a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report myelophthisis on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does D61.82 group to?
When myelophthisis is the principal diagnosis on an inpatient stay, it groups to MS-DRG 841, 821, 822, 825, 842, 824, 840, 820, 823, with relative weights from 0.9948 to 6.2454 depending on complications. Higher weights mean higher Medicare reimbursement.
Is D61.82 a CC or MCC?
CMS lists D61.82 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 41 closely related codes in its exclusion list.
Can D61.82 be reported with D47.1?
Not as a rule. The Excludes1 note on D61.82 lists "idiopathic myelofibrosis (D47.1)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
What HCC is D61.82?
D61.82 (myelophthisis) maps to CMS-HCC Category 109 (Acquired Hemolytic, Aplastic, and Sideroblastic Anemias), commonly written as HCC 109, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 46 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 96.
Does D61.82 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, D61.82 adds a risk adjustment factor of about 1.144 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.529 to 1.815 depending on the payment segment). HCC 109 sits at the top of its hierarchy, so no other condition category supersedes it. See the full factor table on the HCC 109 category page.
